
CLAIMS

1. A compound having the following structure (1):

(1)



its diastereomer, enantiomer, racemic mixture, salts or a combination thereof, for use in the treatment of one or more sodium channel related diseases or disorders in an individual, wherein R is selected from a group comprising hydrogen, alkyl, alkenyl, alkoxy, halo, nitro, cyano, keto, amino, carboxylate, substituted or unsubstituted phenyls, adjacent rings which share a side with the R-bearing group, or a combination thereof, wherein the one or more sodium channel related diseases or disorders is bronchospasm, oesophageal spasm, irritable bowel syndrome (IBS), urinary incontinence or cancer.

2. The compound according to claim 2, wherein the R-bearing group is mono-, di-, or tri-substituted.

3. The compound according to claim 1 or 2, wherein the compound is a threo-diastereomer, a erythro-diastereomer or a mixture of the threo-diastereomer and the erythro-diastereomer.

4. The compound according to any one of claims 1 to 3, wherein R is one or more substituents selected from the group consisting of hydrogen, halogens, substituted or unsubstituted phenyls, and adjacent rings which share a side with the R-bearing group.

5. The compound according to any one of claims 1 to 4, wherein R consists of chlorine substituents at positions 3 and 4.

6. The compound according to any one of claims 1 to 4, wherein R is a *p*-bromo.


7. The compound according to any one of claims 1 to 4, wherein R is a *p*-chloro.

8. The compound according to any one of claims 1 to 4, wherein R is a p-2-naphthyl.

9. The compound according to any one of claims 1 to 4, wherein R is an unsubstituted *p*-phenyl.


10. The compound according to claim 9, wherein the compound has the following structure (2):

(2)



11. The compound according to claim 9, wherein the compound has the following structure (3):

(3)



12. The compound according to claim 9, wherein the compound comprises mixture of structures (2) and (3).

13. The compound according to any one of claims 1 to 12, wherein the compound is capable of inhibiting sodium channel conductance.

14. The compound according to claim 13, wherein the sodium channels are voltage gated sodium channels.

15. The compound according to any one of claims 1 to 14, wherein the compound is capable of inhibiting serotonin receptors and reducing the activity of serotonin receptors.

16. The compound according to any one of claims 1 to 15, wherein the compound is administered orally, parenterally, intramuscularly, intravenously, mucosally or transdermally.

17. The compound according to any one of claims 1 to 16, wherein the use further includes alleviating one or more symptoms of the one or more sodium channel related diseases or disorders, wherein the symptoms include pain, convulsion and inflammation.

18. A composition comprising a compound according to any one of claims 1 to 17, and a pharmaceutical acceptable carrier for use in the treatment of one or more sodium channel related diseases or disorders in an individual, wherein the one or more sodium channel related diseases or disorders is bronchospasm, oesophageal spasm, irritable bowel syndrome (IBS), urinary incontinence or cancer.